- QIAGEN expands QIAstat-Dx platform through a partnership with AstraZeneca to develop companion diagnostics for chronic diseases, enabling fast patient eligibility decisions for precision medicines.
August 28 2024 20:10:11 UTC– QIAGEN partners with AstraZeneca to expand QIAstat-Dx for companion diagnostics in chronic diseases, moving beyond oncology.
QIAstat-Dx allows fast patient eligibility decisions for precision medicines, showcasing QIAGEN’s expertise in companion diagnostic development.
The platform provides rapid results with multiplex real-time PCR and has over 4,000 instrument placements by 2023. QIAGEN collaborates with pharmaceutical companies for tailored companion diagnostics, advancing precision medicine.